HIMS INVESTORS: Hims & Hers Health, Inc. (NYSE:HIMS) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk and the sale of compounded semaglutide [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until August 25, 2025, to request to lead the case [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. Group 3: Allegations and Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. - Following the termination of the partnership by Novo Nordisk on June 23, 2025, due to deceptive practices, Hims & Hers stock price fell by $22.24 per share, a decline of over 34% [5].